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1236.e1 The Journal of Thoracic and CaOpinions among pediatric heart surgeons vary regarding the routine use ofdeep hypothermic circulatory arrest (DHCA) during the surgical manage-ment of neonates and infants with complex congenital heart disease. Cur-
rently, some surgeons use DHCA routinely, others use it selectively, and still others
have essentially abandoned the technique, opting for a perfusion strategy that uses
continuous cardiopulmonary bypass (CPB). While acknowledging that both DHCA
and CPB are abnormal physiologic states associated with risk, surgeons in each
camp believe that their particular management scheme provides the best opportunity
for morbidity-free outcome. This subject has become controversial in recent years,
sometimes it seems to the degree that it is poised to join the ranks of other
well-known contentious topics, like religion and politics, which have become
increasingly unsuitable for polite and civilized discussion. There are three basic
reasons for this development. First, both the quality of cardiac repair and neurode-
velopmental status are at issue. High stakes promote controversy. Second, whereas
in the past DHCA was a necessity, advances in surgical technique and basic
technology have now relegated DHCA to one alternative among several. Having
options leads to controversy. Finally, although DHCA generates strong and differing
opinions among surgeons, there is not nearly enough factual information to defin-
itively support any one view. Uncertainty invites controversy.
What are the hard data that might assist us in determining the relative efficacy of
performing neonatal heart surgery with circulatory support strategies that either
incorporate DHCA or use continuous CPB alone? Because the rationale for choos-
ing one support technique over the other is to achieve the best technical repair with
the least morbidity, it follows that the pertinent data will relate to two main areas:
the quality of the cardiac surgical reconstruction achievable and the total body
morbidity that is incurred with each strategy.
The Quality of Cardiac Reconstruction With DHCA and Continuous CPB
The point has been made by some advocates that DHCA promotes superior
technical outcomes. The main reason given is that the surgical field is unencumbered
by blood and bypass paraphernalia, allowing better visualization of critical struc-
tures. It is commonplace to see statements in publications that advocate the use of
DHCA, referring to “the extraordinary means necessary to maintain continuous
CPB” as a reason to use DHCA. On the other hand, those who prefer continuous
CPB argue that neonatal operations can be performed routinely without compro-
mising visualization, and when the occasional particularly challenging technical
problem or complication arises, the absence of the time limitation that is associated
with DHCA actually might allow a superior technical result. These differing views
might reflect personal styles and preferences, comfort levels with different surgical
skill sets, prior training, or simply attempts to justify the use of one particular
support strategy. In the final analysis, all of the views on both sides of the issue are
purely subjective.
Anecdotal experience, although not necessarily objective, does carry more
weight than subjective opinion alone and can be compelling when it reaches critical
mass. Anecdotal evidence is mounting from many groups that effective repairs can
be achieved with continuous CPB. A personal observation on the basis of extensive
experience with DHCA before 1995 and then exclusive use of continuous CPB since
1995 is that technical outcomes and mortality rates are no different between the two
support strategies, regardless of patient age and size or whether aortic arch recon-
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and includes the use of continuous CPB for all neonatal
cases, including more than 300 involving aortic arch repair.
What about objective data? Are there any that support
one perfusion strategy over the other? Available publica-
tions (both prospective and retrospective studies) in which a
range of operations were performed with both support strat-
egies fail to identify any instance in which technically
unsatisfactory reconstructions or higher mortality rates were
observed more frequently in one circulatory support group
or the other. Many of these publications document out-
comes after neonatal repair with continuous CPB for a
number of lesions, ranging from hypoplastic left heart syn-
drome to transposition of the great arteries, that are equiv-
alent to those achieved with DHCA. Thus there appear to be
no objective data to support the position that DHCA is
justified to achieve optimal technical reconstructions, and in
fact, there are a good deal of indirect data and experience
that run counter to this position.
Morbidity Related to DHCA and Continuous CPB
Both DHCA and continuous CPB represent abnormal phys-
iologic states, and thus both have the potential for causing
morbidity, particularly central nervous system (CNS) mor-
bidity. Although it is easy to demonstrate that the basic
physiologic perturbations related to these 2 support tech-
niques are substantially different, it is much more difficult to
demonstrate differences in CNS clinical outcomes with each
strategy.
Pathophysiology
DHCA causes an immediate cellular energy supply-demand
imbalance, which results in easily identifiable and progres-
sive intracellular metabolic derangements. As stated suc-
cinctly by Ungerleider and Gaynor1 in their editorial in the
May 2004 issue of this Journal, all evidence points to a
linear dose response between the duration of DHCA and
neurophysiologic derangement. After some duration, these
derangements will cause cell death. Before that duration is
reached, if energy supply and demand are brought back into
balance, the metabolic derangements will reverse, and the
cell will recover to survive. The relationship between cell
survival after a sublethal insult and return to cell normality
is, however, complex and not well understood. The issue is
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influence exactly when permanent damage occurs. The most
important of these might well be biologic variability regard-
ing vulnerability to DHCA; however, others include the ef-
fects of deep hypothermia itself, the propensity for neurocel-
lular excitotoxicity, altered cerebrovascular autoregulation,
critical closing pressure, and the no-reflow phenomenon
after DHCA. Thus the likelihood of permanent CNS injury
increases with the duration of DHCA, and at some point,
which varies among individuals, that likelihood becomes
inevitable.
The physiologic perturbations associated with continu-
ous CPB are in many ways more complex than those related
to DHCA. Because the circulation is maintained, the poten-
tial for damage is not related to an obligatory energy supply-
demand imbalance but rather to variable and uncertain
events associated with extracorporeal circulation. Three
hours of CPB, or even 3 days for that matter, might or might
not be associated with irreversible cell damage. The fact that
it is not unusual for a patient to undergo extracorporeal
membrane oxygenation (ECMO) for 3 days or longer and
not have CNS morbidity is a very important observation. It
implies that the physiologic perturbations that lead to mor-
bidity are not inevitable and that duration of CPB, although
a factor, does not play a mandatory role. In other words,
there is no linear dose-response curve. Rather, CPB exposes
the patient to the possibility of events that create morbidity.
It is both logical and quite reasonable to assume that these
morbid events tend to accumulate with increasing duration
of CPB; however, factors other than duration appear to play
equally important, if not more important, roles. Data from
near-infrared spectroscopy cerebral monitoring and trans-
cranial cerebrovascular Doppler monitoring indicate that
microemboli and cerebral malperfusion occur commonly
during many CPB maneuvers that are unrelated to duration
of CPB, such as aortic clamping, starting and stopping CPB,
venting and deairing maneuvers, matching of perfusion flow
rate to body temperature, and arterial and venous cannula
insertion, positioning, and removal.
Despite these effects, there is no denying the ongoing
constant but low instantaneous risk that accumulates with
the duration of CPB. It has been suggested that the causative
link in this association is that duration allows accumulation
of noxious stimuli, such as the microembolic load and the
degree of inflammatory response. Although it seems some-
what intuitive that these factors are causative, on closer
evaluation, this conclusion can be challenged. The duration
of CPB is intimately linked to a number of other variables
that might be difficult to separate out, even with the most
careful multivariate modeling. These variables include the
complexity of the operative procedure itself, technical prob-
lems during CPB that can be difficult to define and docu-
ment, surgical bleeding and magnitude of transfusion, post-
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reserve. All of these variables and others might influence
neurologic outcome, whereas duration of CPB itself might
only be a marker.
One can ask whether there are situations in which the
duration of CPB is not linked to these other potentially
obfuscating cardiac and technical variables. If we look just
outside our own field to the classic neonatal ECMO expe-
rience for lung disease, we might find some insights. ECMO
is normothermic CPB; however, it is performed in the
absence of cardiac disease, and the duration of ECMO is
unrelated to the cardiac surgical variables mentioned above.
The duration of ECMO for neonatal lung disease typically
lasts 100 to 150 hours. A number of carefully performed late
follow-up studies in this patient population focusing on
neurodevelopmental outcome indicate that the majority of
patients are normal at follow-up. Admittedly, deriving in-
ferences from these data and applying them to cardiac
surgery–related CPB must be done with circumspection;
however, the simple observation that many patients who are
subjected to 150 hours of extracorporeal circulation expe-
rience detectable neurodevelopmental consequences is very
important. It implies that in the setting of cardiac surgery,
where variations in CPB duration are measured in minutes
from case to case rather than in hours or days, duration itself
might not be a very important factor in determining neuro-
logic injury.
Does DHCA Replace the Risks of CPB or Add
to Them?
DHCA and continuous CPB are not used simultaneously;
rather, a period of DHCA replaces an equal period of
continuous CPB. Implicit in many discussions is the as-
sumption that when DHCA is used, all of the risks associ-
ated with continuous CPB are eliminated and replaced by
those of DHCA. This is not the case because CPB is always
necessary, even when DHCA is used as an adjunct to
replace part of the CPB run. When DHCA is used, the only
component of continuous CPB that is eliminated from the
overall perfusion management is precisely the duration of
CPB equal to the duration of DHCA. This duration will, by
necessity, be short, measured in minutes. All of the other
continuous CPB maneuvers (and associated risks) remain
and are added to the intrinsic risk related to DHCA. It can
even be argued that some of the continuous CPB risks, for
example those related to the additional cannula manipula-
tion and additional stopping and restarting the pump asso-
ciated with DHCA, actually increase when DHCA is used.
Thus when DHCA is used, it appears that it is most accurate
to view the risk of DHCA as additive to that of CPB, with
very little to be gained by the minor reduction in CPB
duration.
1236.e3 The Journal of Thoracic and Cardiovascular Surgery ● NIs It Possible to Define a Clinically Useful Safe
Period of DHCA?
This requires having the ability to prospectively determine,
in an individual patient, the duration of DHCA that results
in morbidity equal to or less than that of the alternative
perfusion strategy with continuous CPB. This is a daunting
task, and it is easy to argue that we are not even close.
Several factors contribute to this: lack of data, difficulty
with outcome measures, and biologic variability.
Despite some commendable efforts, the data gap is wide.
Two clinical studies from outstanding groups have at-
tempted to characterize the relationship between the dura-
tion of DHCA and CNS morbidity. Both studies are con-
vincing in demonstrating the general relationship between
CNS damage and increasing duration of DHCA. However,
these studies, the best we have in our literature, simply
underscore the limitations that exist in trying to go beyond
this general relationship. In the study by Gaynor and col-
leagues2 in this issue of the Journal, continuous electroen-
cephalographic monitoring is used to identify seizure activ-
ity in neonates undergoing cardiac surgery with either
DHCA or continuous CPB. The authors argue convincingly
that the likelihood of seizure activity increases with the
duration of DHCA. The authors go on to compare the
seizure activity rate in the patients undergoing DHCA with
that in the patients undergoing continuous CPB in an at-
tempt to shed some light on the following important ques-
tion: Are there durations of DHCA for which the CNS risk
is no greater than that for continuous CPB? Unfortunately,
a combination of limited raw data and a poor choice of
statistical modeling invite the casual reader to draw very
misleading conclusions. The raw data consist of 18 outcome
events (presence of electroencephalographic seizure activ-
ity) distributed among 117 patients undergoing DHCA and
2 events among 61 patients undergoing continuous CPB. In
recognition of the limited raw data, the authors have chosen
to separate the patients undergoing DHCA into only two
groups, one in which DHCA duration was less than 40
minutes and the second in which DHCA duration was
greater than 40 minutes. The rates of events are then com-
pared among the continuous CPB group and each of the two
DHCA groups. The analysis shows no difference in the rate
of events between the continuous CPB group and the group
undergoing less than 40 minutes of DHCA, whereas the
group undergoing more than 40 minutes of DHCA showed
a higher rate of events. Strictly speaking, the statistical
analysis is performed correctly; however, the modeling of
the data into the groups undergoing DHCA of greater than
40 minutes and less than 40 minutes is unfortunate, in that
it carries the potential to be unintentionally misleading. In
reality, the lack of difference between the group undergoing
continuous CPB and the group undergoing less than 40
minutes of DHCA does not identify 40 minutes and shorter
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injury is indistinguishable from that with continuous CPB.
To emphasize the arbitrary nature of dividing the patients
undergoing DHCA into two groups, with the split occurring
at 40 minutes’ duration, one can alternatively break the
patients undergoing DHCA in the study by Gaynor and
colleagues2 into three separate groups rather than two: 1 to
25 minutes of DHCA, 26 to 50 minutes of DHCA, and more
than 50 minutes of DHCA. Analysis with this model and
insertion of the actual raw data from the article suggests that
DHCA of 1 to 25 minutes’ duration is indistinguishable
from continuous CPB, but DHCA of 26 to 50 minutes’
duration and more than 51 minutes’ duration are both of
higher risk than continuous CPB. One is tempted (incor-
rectly) to conclude that DHCA of up to 25 minutes’ duration
is just as safe as continuous CPB. The purpose of this
exercise is not to claim a superior modeling of the data,
because the three groups of DHCA treatment have all the
same inadequacies as the two groups of DHCA treatment
chosen by the authors. Neither analysis provides informa-
tion that can be used to define a safe period of DHCA, and
both invite the casual reader to draw incorrect inferences.
The other study that attempts to define a safe period of
DHCA is by Wypij and colleagues,3 published in the No-
vember 2003 issue of this Journal. This analysis, along with
its companion analysis by Bellinger and associates4 in the
same issue, has already been the focus of one mostly favor-
able editorial, the one by Ungerleider and Gaynor1 previ-
ously cited here. The acknowledgements are well deserved
because these analyses represent the latest contributions
from the highly regarded ongoing neurodevelopmental
study of 171 neonatal patients undergoing arterial switch
originally reported by Newburger and coworkers5 in 1993.
The study by Wypij and colleagues3 attempts to define the
relationship between duration of DHCA and neurodevelop-
mental morbidity. The basic message of the analysis is that
the duration of DHCA correlates with increasing neurode-
velopmental deficit in a nonlinear fashion. From 0 to 40
minutes of DHCA, there is no correlation, and at greater
than 40 minutes, there is a linear direct correlation. The
40-minute point itself represents the cutoff point. Durations
of DHCA of less than this have no effect on neurodevelop-
mental outcome and thus are stated to be safe. The statisti-
cally derived 40-minute point has confidence limits, and the
95% lower confidence limit is 32 minutes. The authors
argue that the conservative estimate for the safe period of
DHCA would be less than this 32-minute duration. In many
regards, the analysis represents a landmark article in at-
tempting to define this relationship, and it does provide
important insights. Nonetheless, it has a number of limita-
tions that combine to make it unconvincing in its attempt to
define a safe period of DHCA.
The Journal of Thoracic anFirst, as already noted in the Ungerleider and Gaynor1
editorial, it is difficult to accept the validity of the piecewise
linear regression modeling and its attendant cutoff points
when all available physiologic data suggest a monotonic
linear dose response between the duration of DHCA and
neurometabolic derangement. One is left to wonder whether
the cutoff points represent the threshold of our ability to test
for neurodevelopmental deficit rather than the threshold for
the deficits themselves.
Second, quantitative assessment of neurodevelopment is
not only multidimensional, but it is also extraordinarily
complex within each dimension. As a result, it is orders of
magnitude more difficult than measuring, for example, renal
filtration. Wypij and colleagues3 make a laudable attempt to
assess an array of neurodevelopmental parameters, but even
within this limited and selective array, the data are con-
founding if judged on the basis of the criterion that they
define a safe period of DHCA. Specifically, the 32-minute
value referred to above is based on an analysis that com-
bines the results from 6 different neurodevelopmental tests.
However, when one examines the lower confidence limit for
the cutoff point for each of the 6 neurodevelopmental tests
individually, as shown in Table 2 in the article, the values
ranged much more widely. For example, the value for the
test of fine motor skill was 13 minutes, which is quite
different from 32 minutes. How does one use these data in
the real-life clinical setting? If 29 minutes is safe for speech
development, and 13 minutes is safe for fine motor skill, but
32 minutes is safe if we combine the information from 6
disparate neurodevelopmental tests, what does the cardiac
surgeon tell the parents of a prospective patient? Even more
fundamentally, is it valid to combine the information from
6 disparate neurodevelopmental tests to achieve more data
points so that the 95% confidence limit is narrowed, when
performance on these disparate tests might depend on very
specialized function in different brain areas that might well
have different vulnerabilities to DHCA? Is this combining
of data akin to adding apples and oranges?
Finally, it is also instructive to revisit the raw data in the
analysis of Wypij and colleagues.3 Although patients are
characterized as undergoing DHCA or undergoing low-flow
bypass, all patients in both groups underwent a period of
DHCA. Because of the study design, the large majority of
patients were clustered in two separate ranges of DHCA
duration, roughly 0 to 20 minutes (the low-flow group) and
40 to 70 minutes (the DHCA group). By using estimates
derived from the panels in Figure 1 in this article, it can be
determined that only approximately 16% (25/155) of pa-
tients underwent DHCA for durations of between 21 and 40
minutes. It is not particularly reassuring that the duration of
DHCA that this analysis recommends as the safe period, 32
minutes, falls precisely in the middle of this no man’s land
of raw data.
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and colleagues,3 both the raw data and the modeling are too
limited to define a duration of DHCA that can be considered
safe. These studies do support, however, the general con-
clusion that the risk of CNS morbidity increases with in-
creasing duration of DHCA.
Obtaining adequate amounts of raw data and modeling it
appropriately to answer the important questions might ulti-
mately be achievable. A more vexing problem is defining
outcome measures of CNS injury. This issue has already
been touched on above. Quantitative measurement of CNS
deficit in all its nuances is difficult under any conditions but
particularly in the very young. Thus CNS deficit or damage
is often assessed indirectly by using a number of methods.
These include functional assessment by physical examina-
tion and interactive testing, electroencephalography, imag-
ing studies to assess structural changes, and biochemical
markers. No single test or method is definitive or quantita-
tive with respect to assessing CNS deficit.
This difficulty in assessing outcome is only made more
problematic when attempts are made to use these methods
to project future CNS deficits. It is known that there are
potentially serious long-term effects that result from tran-
sient CNS perturbations detected at the time of extracorpo-
real perfusion. These associations are, however, not com-
pletely understood. As one example, there is accumulating
evidence that transient CNS electrical instability (seizures)
in neonates after DHCA or CPB predicts CNS deficit that is
identifiable only later in life. What we do not yet know is
whether these affected individuals will show even more
profound limitations in CNS reserve later in life, say as
elderly individuals?
Considering what is currently being learned about the
longer-term implications of transient neonatal CNS electri-
cal perturbations in association with DHCA and CPB,
should we be concerned about other transient CNS pertur-
bations that occur during extracorporeal circulation? For
example, the cellular energy supply-demand imbalance as-
sociated with DHCA results in a profound decrease in
high-energy phosphates within minutes of the initiation of
DHCA. These energy stores recover if DHCA is not pro-
longed. Will this transient metabolic CNS perturbation be
shown to be a marker of longer-term CNS deficit in coming
years, just as transient electrical instability has?
The hallmark of this discussion regarding markers of
CNS deficit is uncertainty. Given the uncertainties as de-
scribed, careful consideration must be given to avoiding
techniques that cause measurable CNS perturbations, how-
ever transient, especially when other techniques exist that
do not cause these same perturbations.
Finally, there is the matter of biologic variability. Cur-
rent medical knowledge has difficulty predicting prospec-
tively why an aspirin is tolerated well by one person and
1236.e5 The Journal of Thoracic and Cardiovascular Surgery ● Ncauses gastrointestinal bleeding in another. Considering the
complexity of the CNS, it is almost a certainty that tolerance
to the energy supply-demand imbalance created during
DHCA will show substantial individual variability. Even
with sufficient raw data, ideal outcome measures, and ap-
propriate modeling, a statistically derived safe duration of
DHCA would have, ironically, limited value in the very
situation that is the catalyst for its derivation, that is, as a
prospective predictor in an individual patient. Use of a
duration of DHCA that is derived statistically and is con-
sidered to be, on average, safe might well, in the sensitive
individual, have negative consequences. Prospective utility
of such a value requires the development and mastery of
individual physiologic CNS profiling, something that is not
currently available. Again, the key word is uncertainty.
Uncertainty is acceptable in association with obligatory
techniques but not when alternatives exist.
Summary
When consideration is given to the basic pathophysiology of
DHCA, the many uncertainties inherent in defining a safe
period of DHCA, and the observation that DHCA largely
adds to, rather than replaces, CPB-related risk, it would
seem that there should be some relatively compelling reason
to justify the routine use of DHCA. Yet compelling justifi-
cation does not seem to exist at present. There are alterna-
tive perfusion strategies that are available for essentially
every neonatal operation that the pediatric heart surgeon
performs. These alternative strategies can be used routinely
and reliably without concerns about compromising the tech-
nical surgical repair. Furthermore, the emerging ability to
monitor brain perfusion in real time during continuous CPB
by using various technologies provides the opportunity to
react to unwanted physiologic states, essentially providing
ongoing quality control with immediate feedback.
Having taken this position, I would emphasize that cur-
rently there is no definitive evidence that points to superior
CNS outcomes with either continuous CPB alone or CPB
with short periods of adjunctive DHCA. For the foreseeable
future, we will have to deal with one of those real-life
situations for which complete information is not available to
guide our decision. Thus any decision regarding this choice
will involve weighing some mix of limited directly appli-
cable evidence, peripheral evidence, logic, and experience.
A lack of definitive evidence favoring one strategy or the
other, however, is not proof that the two strategies are equal.
A lack of such evidence can have many causes, only one
being that in reality the two perfusion strategies are equally
safe. Other plausible causes have been discussed in this
editorial.
AUTHOR’S NOTE: The arguments made in this editorial
are based on a review of more than 80 pertinent publica-
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Hanley Editorialstions. A more extensive bibliography is available in the
online version of this editorial.
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